IMMUNITY IN HIV IMMUNIZED AND INFECTED PRIMATES &HUMANS

Information

  • Research Project
  • 3142379
  • ApplicationId
    3142379
  • Core Project Number
    R01AI028065
  • Full Project Number
    5R01AI028065-03
  • Serial Number
    28065
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/1989 - 35 years ago
  • Project End Date
    3/31/1993 - 31 years ago
  • Program Officer Name
  • Budget Start Date
    4/1/1991 - 33 years ago
  • Budget End Date
    3/31/1992 - 32 years ago
  • Fiscal Year
    1991
  • Support Year
    3
  • Suffix
  • Award Notice Date
    9/10/1991 - 33 years ago

IMMUNITY IN HIV IMMUNIZED AND INFECTED PRIMATES &HUMANS

HIV, the causative agent of AIDS, selectively infects CD4+ T cells and macrophages, incapacitates the immune system, and results in opportunistic infections, neoplasms and death. Because T cell mediated immunity (CMI) plays a major role in resistance to infections and recovery from disease by a variety of envelope viruses, it is likely that an effective vaccine against HIV should induce strong HIV specific T CMI responses and perhaps antibodies which, in the presence of complement (C) or by ADCC, can lyse HIV infected cells. The goals of these studies are thus to; 1 and 2) evaluate humans and non-human primates immunized with candidate HIV vaccines for HIV specific T helper (Th) cytotoxic T cells (CTL) and cytotoxic antibodies; 3) evaluate macaques immunized with candidate vaccines against Simian Immunodeficiency Virus (SIV), which causes AIDS in macaques) for SIV-specific , The CTL and cytotoxic antibodies; 4) compare HIV infected chimpanzees (which do not develop AIDS) with humans for the presence of HIV responses; 5) determine whether HIV infected humans or SIV infected macaques have circulating CTL which can lyse normal CD4+ cells (perhaps contributing to the loss of CD4+ cells during infection) and attempt to define the target antigens for these CTL; 6) determine whether in victor stimulation of human, chimp or macaque T cells with pooled allogeneic normal cells can result in CTL lytic for autologous HIV or SIV infected cells; 7) produce and evaluate HIV- 1 isolates, cross-linked to MAb to CD3 or CD16 on lymphocytes, for their ability to focus human or chimp PBL to lyse HIV-1 infected cells and to produce MAb heteroconjugates reactive with HIV-1 and SIV and determine if they enable human an macaque PBL to lyse HIV- 2 and SIV infected cells. The first four aims of this proposal related to the development of vaccines against immunodeficiency viruses and elucidation of antigens which elicit Th and CTL responses. The fourth and fifth aims concern possible differences of HIV CMI immune responses and autoimmunity between chimps and humans infected with HIV and may relate to the fact that HIV causes disease in humans but not in chimps. The fifth, sixth and seventh aims may provide results leading to immunotherapeutic approaches for HIV infections.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ARR
  • Study Section Name
  • Organization Name
    ONCOGEN
  • Organization Department
  • Organization DUNS
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    98121
  • Organization District
    UNITED STATES